Alnylam Pharmaceuticals, a company specializing in RNAi therapeutics, has declared the issuance of a notice of allowance by the United States Patent and Trademark Office (USPTO) for the patent application number 12/813,448 that covers the company’s in-house second generation lipid nanoparticle platform and the MC3 lipid.
As part of its Alnylam 5x15 product strategy, Alnylam Pharmaceuticals uses its proprietary second generation lipid nanoparticle delivery platform in development programs such as ALN-TTR02, an RNAi therapeutic that targets PCSK9 for treating severe hypercholesterolemia, and ALN-TTR02, an RNAi therapeutic that targets transthyretin (TTR) for treating transthyretin-mediated amyloidosis (ATTR).
This newly allowed patent application comprises 30 claims encompassing formulations and composition of substances of MC3, and procedures of utilizing these formulations and compositions. Inventors listed in the patent application include Alnylam Pharmaceuticals’ Muthusamy Jayaraman, Jayaprakash K. Narayannair, Kallanthottathil G. Rajeev, Muthiah Manoharan, William Cantley, Xiaojun Qin, Joseph Robert Dorkin and Akin Akinc, and AlCana Technologies’ Steven Ansell and Jianxin Chen.
Alnylam Pharmaceuticals’ Senior Vice President and Chief Business Officer, Laurence Reid stated that the company is happy about the USPTO’s notice of allowance for this crucial patent covering the company’s second generation lipid nanoparticles, thus recognizing the uniqueness of the MC3 lipid that delivers RNAi therapeutics systemically.
Reid further said that these unique lipid nanoparticles demonstrate meaningful enhancements in therapeutic index and potency for RNAi therapeutics, as witnessed by the company’s latest human clinical results with ALN-PCS, and also characterize the company’s lipid nanoparticle platform for developing ALN-TTR02 as well as other Alnylam 5x15 programs.
Source: http://www.alnylam.com